T1000	Negation 1579 1590	rather than
E1000	Negation:T1000 Scope:T1001
T1001	Span 1579 1609	rather than RXR-RXR homodimers
T1002	Negation 1355 1366	rather than
E1001	Negation:T1002 Scope:T1003
T1003	Span 1355 1609	rather than an RAR-specific, agonist induces terminal granulocytic differentiation of MPRO promyelocytes, and this differentiation is associated with activation of DNA response elements corresponding to RAR-RXR heterodimers rather than RXR-RXR homodimers
T1004	Speculation 1879 1885	either
E1002	Speculation:T1004 Scope:T1005
T1005	Span 1859 2014	agonist is inactive either in potentiating IL-3-mediated commitment of EML cells to the granulocyte lineage or in transactivating RAR-RXR response elements
T1006	Speculation 1677 1687	suggesting
E1003	Speculation:T1006 Scope:T1007
T1007	Span 1677 1765	suggesting extensive cross-talk between the partners of the RXR -RARalpha403 heterodimer
T1008	Negation 2330 2333	not
E1004	Negation:T1008 Scope:T1009
T1009	Span 2330 2369	not in the committed MPRO promyelocytes
T1010	Speculation 2077 2091	indicates that
E1005	Speculation:T1010 Scope:T1011
T1011	Span 2077 2182	indicates that the multipotent EML cells harbor substantial nuclear hormone receptor coactivator activity
T1012	Speculation 2503 2508	might
E1006	Speculation:T1012 Scope:T1013
T1013	Span 2503 2650	might account for the differential activation of the RXR-RARalpha403 heterodimers that we observed at these different stages of myeloid development
T1014	Speculation 2371 2386	indicating that
E1007	Speculation:T1014 Scope:T1015
T1015	Span 2371 2650	indicating that differences in HDAC-containing repressor complexes in these two closely related but distinct hematopoietic lineages might account for the differential activation of the RXR-RARalpha403 heterodimers that we observed at these different stages of myeloid development
